Silver Bullet Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The standard of care for osteomyelitis has not changed over the past half century: long-term intravenous antibiotics with multiple agents and doses administered daily and typically lasting a full 12 weeks, followed by oral medications for an additional several months to a year. Silver Bullet Therapeutics Inc. is developing a temporary, implantable silver-eluting implant to fight infection in tandem with IV antibiotics. The company's founders say it should shorten the duration of IV therapy by half.
You may also be interested in...
Start-Up Previews (11/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.
Vagisil Marketer Combe Enters Personal Lubricant Market With BioFilm Acquisition
Vagisil and BioFilm’s Astroglide “demonstrate very high levels of brand awareness, brand loyalty, and repeat purchase, and continue to attract new and younger consumers into the category,” firms say.